NASDAQ:EGRX - Eagle Pharmaceuticals Stock Price, News, & Analysis Sign in or create an account to add this stock to your watchlist. Get Started $50.49 +0.02 (+0.04 %) (As of 11/13/2018 03:31 PM ET)Previous Close$50.49Today's Range$49.85 - $51.4052-Week Range$46.88 - $85.66Volume4,898 shsAverage Volume348,708 shsMarket Capitalization$774.74 millionP/E Ratio15.18Dividend YieldN/ABeta1.72 ProfileDiscussionAnalyst RatingsChartEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsSocial Media Share on FacebookShare on TwitterShare on LinkedInShare on RedditShare on StocktwitsPrint this articleShare by Email Eagle Pharmaceuticals, Inc., a specialty pharmaceutical company, focuses on developing and commercializing injectable products primarily in the critical care and oncology areas in the United States. The company offers argatroban for heparin-induced thrombocytopenia; Ryanodex for malignant hyperthermia; non-alcohol docetaxel injection, a chemotherapeutic agent for breast, non-small cell lung, prostate, head, and neck cancers/gastric adenocarcinoma; and Bendeka for chronic lymphocytic leukemia (CLL) and indolent B-cell non-Hodgkin's lymphoma (NHL). Its product candidates includes include EP-3101, (bendamustine ready-to-dilute) for CLL and indolent B-cell NHL; EP-4104, a dantrolene sodium for exertional heat stroke; EGL-4104-C-1702, dantrolene sodium for drug induced hyperthermia; EP-5101 (pemetrexed) for lung cancer and mesothelioma; and EGL-5385-C-1701 (fulvestrant) for breast cancer. Eagle Pharmaceuticals, Inc. was founded in 2007 and is headquartered in Woodcliff Lake, New Jersey. Receive EGRX News and Ratings via Email Sign-up to receive the latest news and ratings for EGRX and its competitors with MarketBeat's FREE daily newsletter. Industry, Sector and Symbol Stock Exchange NASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:EGRX Previous Symbol CUSIPN/A Webwww.eagleus.com Phone201-326-5300 Debt Debt-to-Equity Ratio0.20 Current Ratio5.59 Quick Ratio5.38 Price-To-Earnings Trailing P/E Ratio15.18 Forward P/E Ratio24.87 P/E GrowthN/A Sales & Book Value Annual Sales$236.71 million Price / Sales3.18 Cash Flow$3.7511 per share Price / Cash13.46 Book Value$12.01 per share Price / Book4.20 Profitability EPS (Most Recent Fiscal Year)$3.37 Net Income$51.94 million Net Margins13.92% Return on Equity17.62% Return on Assets12.23% Miscellaneous Employees108 Outstanding Shares14,910,000Market Cap$774.74 million OptionableOptionable Eagle Pharmaceuticals (NASDAQ:EGRX) Frequently Asked Questions What is Eagle Pharmaceuticals' stock symbol? Eagle Pharmaceuticals trades on the NASDAQ under the ticker symbol "EGRX." How will Eagle Pharmaceuticals' stock buyback program work? Eagle Pharmaceuticals announced that its board has initiated a share buyback plan on Thursday, August 10th 2017, which allows the company to repurchase $100,000,000.00 in shares, according to EventVestor. This repurchase authorization allows the company to repurchase up to 13.3% of its shares through open market purchases. Shares repurchase plans are usually an indication that the company's leadership believes its stock is undervalued. How were Eagle Pharmaceuticals' earnings last quarter? Eagle Pharmaceuticals Inc (NASDAQ:EGRX) announced its earnings results on Thursday, November, 1st. The specialty pharmaceutical company reported $1.18 EPS for the quarter, beating the Thomson Reuters' consensus estimate of $0.91 by $0.27. The specialty pharmaceutical company earned $51.34 million during the quarter, compared to analysts' expectations of $52.70 million. Eagle Pharmaceuticals had a return on equity of 17.62% and a net margin of 13.92%. The company's revenue was down 18.5% compared to the same quarter last year. During the same period last year, the company posted $1.22 EPS. View Eagle Pharmaceuticals' Earnings History. When is Eagle Pharmaceuticals' next earnings date? Eagle Pharmaceuticals is scheduled to release their next quarterly earnings announcement on Monday, February 25th 2019. View Earnings Estimates for Eagle Pharmaceuticals. What guidance has Eagle Pharmaceuticals issued on next quarter's earnings? Eagle Pharmaceuticals updated its third quarter earnings guidance on Tuesday, October, 30th. The company provided earnings per share guidance of $1.18 for the period, compared to the Thomson Reuters consensus estimate of $0.97. The company issued revenue guidance of $51 million, compared to the consensus revenue estimate of $55.23 million. What price target have analysts set for EGRX? 4 Wall Street analysts have issued twelve-month target prices for Eagle Pharmaceuticals' stock. Their forecasts range from $52.00 to $80.00. On average, they anticipate Eagle Pharmaceuticals' share price to reach $62.50 in the next year. This suggests a possible upside of 23.9% from the stock's current price. View Analyst Price Targets for Eagle Pharmaceuticals. What is the consensus analysts' recommendation for Eagle Pharmaceuticals? 4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Eagle Pharmaceuticals in the last year. There are currently 3 hold ratings and 1 buy rating for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for Eagle Pharmaceuticals. What are Wall Street analysts saying about Eagle Pharmaceuticals stock? Here are some recent quotes from research analysts about Eagle Pharmaceuticals stock: 1. According to Zacks Investment Research, "Eagle Pharmaceuticals, Inc. is a specialty pharmaceutical company. It focuses on developing and commercializing injectable products primarily in the critical care and oncology areas in the United States. The Company markets EP-1101 to treat heparin-induced thrombocytopenia. It develops EP-3101, EP-3102, Ryanodex and EP-4104. Eagle Pharmaceuticals, Inc. is based in Woodcliff Lake, New Jersey. " (10/18/2018) 2. Cantor Fitzgerald analysts commented, "Eagle has carved out a leading position in the specialty pharma market, via its 505(b) (2) strategy. We expect upwards earnings revisions to the Street’s current forecasts as the company advances its pipeline and provides date-certain launch timeframes for its pipeline. Valuation Summary We use a blend of DCF and multiples (EV/EBITDA) analysis to get to our 12-month price target of $80." (10/3/2018) 3. Mizuho analysts commented, "We don’t yet have this product in our model, and don’t expect it to be a meaningful revenue generator because Treanda powder currently has minimal market share. Big bag" may provide insurance if Eagle fails to bar Treanda generics from the market via its Orphan Drug litigation, in our view. The Fulvestrant clinical trial is fully enrolled, and data are expected in the fall. Additionally, the FDA accepted Eagle’s Vasostrict ANDA, which Endo indicated would be subject to the full litigation pathway. We have no estimates for the Ryanodex program for nerve agent exposure and note that Eagle did not provide an update on its drug- induced hyperthermia program, which we believe could get dropped. We summarize 1Q:18 performance below and reiterate our Underperform rating." (5/10/2018) Has Eagle Pharmaceuticals been receiving favorable news coverage? Headlines about EGRX stock have been trending somewhat positive recently, InfoTrie reports. The research group ranks the sentiment of media coverage by analyzing more than six thousand news and blog sources. The firm ranks coverage of publicly-traded companies on a scale of negative five to five, with scores nearest to five being the most favorable. Eagle Pharmaceuticals earned a news impact score of 1.4 on InfoTrie's scale. They also gave press coverage about the specialty pharmaceutical company a news buzz of 10.0 out of 10, indicating that recent media coverage is extremely likely to have an impact on the stock's share price in the immediate future. Who are some of Eagle Pharmaceuticals' key competitors? Some companies that are related to Eagle Pharmaceuticals include Endo International (ENDP), Madrigal Pharmaceuticals (MDGL), Ascendis Pharma A/S (ASND), Blueprint Medicines (BPMC), Ultragenyx Pharmaceutical (RARE), Mallinckrodt (MNK), Supernus Pharmaceuticals (SUPN), ACADIA Pharmaceuticals (ACAD), Myokardia (MYOK), Akcea Therapeutics (AKCA), Allakos (ALLK), Heron Therapeutics (HRTX), Xencor (XNCR), Global Blood Therapeutics (GBT) and Prestige Consumer Healthcare (PBH). Who are Eagle Pharmaceuticals' key executives? Eagle Pharmaceuticals' management team includes the folowing people: Mr. Scott L. Tarriff, CEO & Director (Age 58)Mr. David M. Pernock, Pres & Chief Operating Officer (Age 65)Mr. Pete A. Meyers, Chief Financial Officer (Age 48)Dr. Adrian Hepner, Exec. VP & Chief Medical Officer (Age 57)Mr. Daniel O'Connor, Exec. VP of Biologics and Corp. Devel. (Age 38) Who are Eagle Pharmaceuticals' major shareholders? Eagle Pharmaceuticals' stock is owned by a variety of of institutional and retail investors. Top institutional investors include Janus Henderson Group PLC (12.62%), BlackRock Inc. (11.68%), Iridian Asset Management LLC CT (6.27%), Victory Capital Management Inc. (3.40%), Rothschild & Co. Asset Management US Inc. (2.68%) and FMR LLC (1.60%). Company insiders that own Eagle Pharmaceuticals stock include David Pernock, Douglas L Braunstein, Pete A Meyers, Proquest Investments Iv, LP, Richard A Edlin, Sander A Flaum, Sander A Flaum, Steven B Ratoff and Steven L Krill. View Institutional Ownership Trends for Eagle Pharmaceuticals. Which major investors are selling Eagle Pharmaceuticals stock? EGRX stock was sold by a variety of institutional investors in the last quarter, including LSV Asset Management, Victory Capital Management Inc., FMR LLC, C WorldWide Group Holding A S, Bellevue Group AG, Rice Hall James & Associates LLC, First Eagle Investment Management LLC and Janus Henderson Group PLC. View Insider Buying and Selling for Eagle Pharmaceuticals. Which major investors are buying Eagle Pharmaceuticals stock? EGRX stock was purchased by a variety of institutional investors in the last quarter, including BlackRock Inc., Iridian Asset Management LLC CT, Scout Investments Inc., Skandinaviska Enskilda Banken AB publ , Carillon Tower Advisers Inc., Canada Pension Plan Investment Board, Dimensional Fund Advisors LP and JPMorgan Chase & Co.. Company insiders that have bought Eagle Pharmaceuticals stock in the last two years include David Pernock, Douglas L Braunstein, Pete A Meyers and Richard A Edlin. View Insider Buying and Selling for Eagle Pharmaceuticals. How do I buy shares of Eagle Pharmaceuticals? Shares of EGRX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab. What is Eagle Pharmaceuticals' stock price today? One share of EGRX stock can currently be purchased for approximately $50.43. How big of a company is Eagle Pharmaceuticals? Eagle Pharmaceuticals has a market capitalization of $774.74 million and generates $236.71 million in revenue each year. The specialty pharmaceutical company earns $51.94 million in net income (profit) each year or $3.37 on an earnings per share basis. Eagle Pharmaceuticals employs 108 workers across the globe. What is Eagle Pharmaceuticals' official website? The official website for Eagle Pharmaceuticals is http://www.eagleus.com. How can I contact Eagle Pharmaceuticals? Eagle Pharmaceuticals' mailing address is 50 TICE BOULEVARD SUITE 315, WOODCLIFF LAKE NJ, 07677. The specialty pharmaceutical company can be reached via phone at 201-326-5300 or via email at [email protected] MarketBeat Community Rating for Eagle Pharmaceuticals (NASDAQ EGRX)Community Ranking: 3.1 out of 5 ( )Outperform Votes: 343 (Vote Outperform)Underperform Votes: 203 (Vote Underperform)Total Votes: 546MarketBeat's community ratings are surveys of what our community members think about Eagle Pharmaceuticals and other stocks. Vote "Outperform" if you believe EGRX will outperform the S&P 500 over the long term. Vote "Underperform" if you believe EGRX will underperform the S&P 500 over the long term. You may vote once every thirty days. This page was last updated on 11/13/2018 by MarketBeat.com StaffFeatured Article: How can investors find ex-dividend dates?